Boston Scientific reports positive data from five-year Watchman study

Boston Scientific has announced the findings of a new clinical trial that highlights the long-term benefits of its Watchman left atrial appendage closure device.

Final five-year outcomes data from the PREVAIL study has shown that Watchman can be a safe and effective alternative to long-term warfarin therapy, offering comparable stroke risk reduction for patients with non-valvular atrial fibrillation.

This backed up the findings of the previous PROTECT-AF study, with the completion of five-year follow-up in both trials leading to a meta-analysis combining data from the 1,114 randomised patients from the two studies, totalling 4,343 patient-years in all.

The findings showed that Watchman effectively reduced non-procedure related major bleeding, disabling or fatal stroke, and led to a reduction in mortality rates, in addition to the stroke prevention benefits.

Dr Kenneth Stein, senior vice-president and chief medical officer for rhythm management and global health policy at Boston Scientific, said: "The data presented today lend additional credence to the long-term safety and efficacy for the Watchman device."

With over 20 years of experience within the medical devices market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current medical device roles we have available, you can search for the latest job roles, register your details, or contact the team today.